Associations fixes de médicaments
Auteur : Dr. Carmelo Lafuente
Dernière mise à jour : 25/09/2023
Cet outil permet de chercher des association fixes de médicaments commércialisées en France disponibles pour un principe actif ou une classe thérapeutique donnés.
Les associations fixes de médicaments peuvent être utiles pour réduire le nombre de comprimés qu'un patient doit prendre et favoriser une bonne observance du traitement.
Des études montrent des meilleurs résultats cliniques avec l'utilisation d'associations dans les maladies cardiovasculaires (Wang 2023, SECURE 2022). Elles sont aussi très utilisées dans certaines maladies infectieuses ; VIH, hépatite virales, tuberculose *.
(* la liste de spécialités pour ce volet est encore en construction)
Comment chercher :
- Cherchez par principe actif, nom commercial, classe thérapeutique ou l'indication principale
- Vous pouvez utiliser des mots incomplets : rami, amlo, metfor ...
- Il est possible d'utiliser des abbreviations courantes de classes thérapeutiques : iec, ara2, dpp4 ...
- Vous pouvez ajouter un dosage aux critères de rechercher. Si vous cherchez un dosage précis d'un principe actif, utilisez ce format : ramipril_5mg, atorvastatine_40mg ...
Références
-
Wang 2023. Revue systématique : Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension: A Systematic Review and Meta-analysis. JAMA CardiolSeven trials with a total of 1918 patients (..) were included. Four trials involved triple-component low-dose combination (LDC) and 3 involved quadruple-component LDC. .. At 4 to 12 weeks follow-up, LDC was associated with a greater mean reduction in SBP than initial monotherapy or usual care (mean reduction, 7.4 mm Hg ..) .. LDC was associated with a higher proportion of participants achieving BP less than 140/90 mm Hg compared to both monotherapy or usual care (66% vs 46%) .. LDCs with 3 or 4 antihypertensives were an effective and well-tolerated BP-lowering treatment option for the initial or early management of hypertension
-
SECURE 2022. Essai randomisé de grande taille : Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J MedA total of 2499 patients underwent randomization and were followed for a median of 36 months. A primary-outcome event [cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or urgent revascularization] occurred in 118 of 1237 patients (9.5%) in the polypill group and in 156 of 1229 (12.7%) in the usual-care group (hazard ratio, 0.76 ..) .. Treatment with a polypill containing aspirin, ramipril, and atorvastatin within 6 months after myocardial infarction resulted in a significantly lower risk of major adverse cardiovascular events than usual care.
-
GS-US-380 2020. Essai randomisé : Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection. Lancet HIV629 participants were randomly assigned and treated in study 1 (..) and 645 in study 2 (..). At week 144, bictegravir, emtricitabine, and tenofovir alafenamide was non-inferior to both dolutegravir-containing regimens for efficacy. 82% participants had plasma HIV-1 RNA less than 50 copies per mL in the bictegravir, emtricitabine, and tenofovir alafenamide group and ..84%.. in the dolutegravir, emtricitabine, and tenofovir alafenamide group (difference -1·9%, -7·8 to 3·9). .. These long-term data support the use of [fixed-dose] bictegravir, emtricitabine, and tenofovir alafenamide as a safe, well tolerated, and durable treatment for people with HIV